1. Microbiology

Category Archives: Microbiology

The Ultimate STEM PROFESSIONAL Terry Morris, D.V.M., MS and Ph.D in Microbiology – Video

Posted on by


The Ultimate STEM PROFESSIONAL Terry Morris, D.V.M., MS and Ph.D in Microbiology
Dr. Terry Morris blends her love for science and people with her business VETS TO VETS. A wonderful veterinarian, microbiologist, immunologist, and humanitar...

By: GHCINTL

See the article here:
The Ultimate STEM PROFESSIONAL Terry Morris, D.V.M., MS and Ph.D in Microbiology - Video

HSA concerned about Burnaby lab closure

Posted on by

5/3/2013

The President of the Health Sciences Association says he's alarmed by a plan to shut down the microbiology lab at Burnaby General Hospital and have the service centralized elsewhere, possibly in Surrey.

"Are we restructuring health care via calculator, via accounting principals, or are we doing it because it's the best practises for clincal service?"

Reid Johnson says given Burnaby General's history of deadly C-difficle outbreaks, this won't add up to the best care for patients.

"What we have seen in other hospitals where the microbiology lab's ability to test for these things has been taken out of the hospital...there is a time delay, so you don't know how to treat people."

He says Burnaby General Hospital has had 84 or more C-difficile deaths over the last couple of years.

Lower Mainland Labs says they are not shutting down the lab, despite claims from the union.

Executive Director of Pathology Edward Ratnarah says staff are not going to be affected when a portion of the lab is moved to Royal Columbian Hospital.

"We are not shutting down the whole microbiology lab we are only shutting down a portion of it and we are moving just the analytical portion of the testing to Royal Columbian. The consultative services, all the medical staff, they are all remaining, and the staff services that is also remaining at Burnaby hospital."

Ratnarah says consolidation will address problems with an aging work force which is leading to challenges in retaining staff.

The rest is here:
HSA concerned about Burnaby lab closure

Edison State professor takes his research to Malaysia

Posted on by

FORT MYERS, Fla.- Edison State College Microbiology Professor, Dr. Robert Furler is going to Malaysia. He was awarded a scholarship to present his research with the UCLA AIDS Institute at the HIV Cure Symposium and International AIDS Conference from June 29 through July 3. The 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention is organized by the IAS, in partnership with The Centre of Excellence for Research in AIDS.

Dr. Furlers research focuses on the Nef protein, which is one of the main proteins in the Human Immunodeficiency Virus (HIV). HIV infects cells that are central to the immune system, and the immune system protects the body from dangerous microbes like viruses, bacteria, and fungi. After HIV destroys the immune system, the individual is more susceptible to normal infections. This research investigates Nef, which is one of the proteins used by HIV to evade the immune system. The Nef protein is a critical component of HIV which helps the virus hide from the normal immune system.

Dr. Furler received his Bachelor of Science degree in Cell & Molecular Biology with a Minor in Chemistry from San Francisco State University and his Ph.D. in Microbiology, Immunology, & Molecular Genetics from the University of California. His work has been published in a variety of professional publications, and he has also received several scholarships to international seminars and professional events.

See more here:
Edison State professor takes his research to Malaysia

Electron-beam pasteurization of raw oysters may reduce viral food poisoning

Posted on by

Public release date: 30-Apr-2013 [ | E-mail | Share ]

Contact: Dr. Suresh Pillai s-pillai@tamu.edu 979-458-1640 Texas A&M AgriLife Communications

COLLEGE STATION According to the Centers for Disease Control, about one in six Americans gets food poisoning each year. Additionally, virus infection risks from consumption of raw oysters in the U.S. are estimated to cost around $200 million a year.

To address the issue of health risk from eating raw oysters, Texas A&M University graduate student Chandni Praveen, along with Texas A&M AgriLife Research scientist Dr. Suresh Pillai and a team of researchers from other agencies and institutions, studied how electron-beam pasteurization of raw oysters may reduce the possibility of food poisoning through virus.

Other entities involved in the study included the U.S. Department of Agriculture, the U.S. Food and Drug Administration and University of Texas School of Public Health-El Paso regional campus.

The results of this study will be published in the June issue of the leading microbiology journal, Applied and Environmental Microbiology.

"The study was performed using a human norovirus surrogate called murine norovirus (NoV), and a hepatitis A (HAV) virus along with advanced quantitative microbial risk assessment tools," explained Pillai, professor of microbiology and director of the National Center for Electron Beam Research at Texas A&M University. "A salient feature of e-beam pasteurization technology is that it uses commercial electricity to generate the ionizing radiation that inactivates the viruses. It is a green technology because no chemicals are involved."

Pillai said the FDA already has approved the use of electron beam technology as a pathogen intervention strategy to control the naturally occurring Vibrio vulnificus bacterial pathogen in shellfish.

According to the FDA, raw oysters contaminated with Vibrio vulnificus can be life threatening or even fatal when eaten by someone with liver disease, diabetes or a weakened immune system.

"We're all for any means of technology that enhances the safety of our product," said Sal Sunseri, co-owner of P&J Oysters and a representative of the Louisiana Oyster Dealers and Growers Association. "While we provide a safe product, we know there are at-risk groups, and that processing methods like freezing, high-pressure treatment and electron-beam irradiation reduce or eliminate the risk for those groups and enhance the overall safety of our product."

Read the original:
Electron-beam pasteurization of raw oysters may reduce viral food poisoning

NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver

Posted on by

HUBBARD, Ohio--(BUSINESS WIRE)--

NanoLogix Inc. (NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria announces that they will exhibit their microbial detection and diagnostic technologies at both the Food Safety Summit in Baltimore 30 April May 2 and the American Society for Microbiology Annual Meeting in Denver 18-21 May.

The Company will exhibit at booth 924 in the Baltimore Convention Center, Halls A-C.

Further information is available at: http://www.foodsafetysummit.com/

In Denver, the Company will exhibit at booth 1244 in the Colorado Convention Center, Halls A and B. Further information on the event is available at: http://gm.asm.org/

NanoLogix has posted an operations update for 2012-13 at: http://www.nanologix.com.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

For more information visit http://www.nanologix.com.

Excerpt from:
NanoLogix to Exhibit at Food Safety Summit in Baltimore and American Society for Microbiology Annual Meeting in Denver

Protein improves efficacy of tumor-killing enzyme

Posted on by

Public release date: 30-Apr-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Scientists have devised a method for delivering tumor cell-killing enzymes in a way that protects the enzyme until it can do its work inside the cell. In their study in mBio, the online open-access journal of the American Society for Microbiology, researchers assembled microscopic protein packages that can deliver an enzyme called PEIII to the insides of cells. By attaching a protein called ubiquitin to the enzyme, they were able to protect it from degradation by the cell, allowing the enzyme to complete its mission. The results indicate that ubiquitin may be a useful addition to targeted toxins.

Although researchers have been developing tumor-directed "targeted toxins" for decades, their success has been hindered by technical problems, including inadequate tumor specificity, low efficiency of delivery to the interior of the cell (also called the cytosol), and other issues. In this study, researchers from the National Institute of Allergy and Infectious Diseases sought to improve the persistence of the enzyme in the cytosol.

They created bundles of proteins designed to carry this out. The targeted toxin assembly included two components the researchers have used before in targeted toxins: the "killing" enzyme PEIII, and a set of targeting proteins called LFn that deliver the PEIII enzyme via pores to the inside of the cell. The LFn delivery system was engineered to specifically target and attach to tumor cells.

The third component in the bundle was a new addition: ubiquitin, a small protein that is normally used by cells to target waste proteins for degradation. The researchers inserted ubiquitin in between the LFn and the PEIII, then tested the bundle on mice with tumors. The idea was to use the cell's own ubiquitin-cleaving enzymes to cut the ubiquitin off and free up the PEIII enzyme once it's inside the cell.

The system worked. Tumor growth was inhibited in mice treated with targeted toxins that either carried the wild-type ubiquitin or engineered ubiquitin without lysine residues in it, a change that should prevent it from being degraded by the cell. The addition of ubiquitin enhanced the ability of the PEIII enzyme to persist inside the cell thereby enhancing its potency. And the ubiquitin didn't seem to hinder the efficiency of delivering the PEIII inside the cell.

As an added bonus, the addition of ubiquitin reduced the toxicity of the targeted toxin to non-tumor tissues.

The authors point out that the use of ubiquitin linkers shows considerable promise and could be an effective strategy for enhancing the potency of tumor-targeting toxins for use in patients. In research currently underway, they are attempting to improve on the system by making changes to the ubiquitin that allow it to unfold appropriately inside the cell.

###

Read the original here:
Protein improves efficacy of tumor-killing enzyme

Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology

Posted on by

BERLIN--(BUSINESS WIRE)--

At the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker shows new capabilities of the MALDI Biotyper platform.

The MALDI Biotyper (MBT) is the market-leading system for microbial identification based on MALDI-TOF mass spectrometry. It is widely used in clinical microbiology, industrial microbiology, animal health and food safety and has become the broadly accepted laboratory standard for next generation microbial identification. While conventional biochemical testing takes time-consuming incubation after selection of the microbes from the culture plate, the MALDI Biotyper allows for an instantaneous identification of colonies from a plate. The MALDI Biotyper system covers a broad range of more than 4,600 microbial isolates from gram-negative bacteria, gram-positive bacteria, yeasts, multicellular fungi and mycobacteria. It is broadly applicable as a standard identification tool in various fields of microbiology. Microbial identification with the MALDI Biotyper is done using a proteomic fingerprint. This unique species-specific pattern is automatically compared with reference spectra in the MALDI Biotyper library. In addition, the MALDI Biotyper supports the Open Microbiology Concept which allows customers to generate their own database entries from regional isolates via a push-button storage in a customer-specific sub-library.

The new second edition of the MBT Mycobacteria Library adds another 140 isolates from 37 new species. The library is fully compatible with all standard cultivation media for mycobacteria, such as solid Lwenstein-Jensen medium or in liquid culture using the MGIT system from Becton Dickinson. With these added capabilities the MALDI Biotyper covers now more than 130 species of mycobacteria.

The new MALDI Biotyper Pilot accessory complements the satellite software to a complete, barcoded and paperless workflow. The MBT Pilot is used for light-guided manual target preparation using cross hairs to indicate the next position for preparation on the MALDI target. Barcoding of the MALDI target and the sample, along with multiple isolate support, ensure that the complete process is fully traceable.

The new MALDI Biotyper Galaxy performs a quality-controlled automated deposition of the MALDI matrix onto the target plate. After the preparation it scans the target positions and checks if each spot is optimally prepared for MALDI Biotyper measurements. The MBT Galaxy has a seamless integration into the MBT server coupled with on-board barcode reading and automated loading of the associated project work list. Both MBT Pilot and MBT Galaxy are scheduled to be commercially available in 2013.

The revolutionary MALDI-Biotyper-Spectrum-Beta-Lactamase workflow (MSBL) enables users to perform patented functional beta-lactam antibiotic resistance testing for selected antibiotics on the MALDI Biotyper platform. The cleavage of beta-lactam antibiotics, like penicillins, 3rd generation cephalosporins or carbapenems by resistant bacteria leads to specific mass shifts of the cleaved products. Such mass shifts can be observed and monitored using the MALDI Biotyper, and automatically interpreted with the MSBL software module, which is also expected to be commercially availability later this year.

Dr. Wolfgang Pusch, Executive Vice President - Microbiology Business at Bruker Daltonics, explained: At the 2013 ECCMID in Berlin, Bruker is again showcasing very significant developments to further improve and streamline the established MALDI Biotyper workflow. The MALDI Biotyper Pilot and MALDI Biotyper Galaxy automation accessories add further functionality for quality control and traceability and at the same time reduce the manual workload of the operators. The MSBL method is another major step ahead to apply the MALDI Biotyper platform also in the fields of hospital hygiene and epidemiology to get fast results concerning resistance of bacteria to selected antibiotics.

Professor David Livermore, University of East Anglia, Norwich, UK, commented: I am very excited about the potential to detect beta-lactamases - and maybe other resistances - as well as to identify microbes by MALDI-TOF mass spectrometry. Early information about resistance is very important to antibiotic stewardship.

About the Bruker MALDI Biotyper The dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States of America the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures.

Read the original post:
Bruker Expands Capabilities of MALDI Biotyper Platform for Microbiology

American Academy of Arts and Sciences Elects Martin J. Blaser, MD, Professor of Medicine and Microbiology, to 2013 …

Posted on by

NYU School of Medicine Professor Joins World Leaders in Academia, Business, Public Affairs, Humanities and the Arts

Newswise New York, NY, April 25, 2013 NYU School of Medicine is pleased to announce that The American Academy of Arts and Sciences (AMACAD) has elected Martin J. Blaser, MD, the George and Muriel Singer Professor of Medicine, professor of microbiology, and director of the Human Microbiome Program at NYU Langone, to this years class of members. The new class will be inducted at a ceremony on October 12, 2013, at the Academys headquarters in Cambridge, Massachusetts.

Members of the 2013 class include winners of the Nobel Prize; National Medal of Science; the Lasker Award; the Pulitzer and the Shaw prizes; the Fields Medal; MacArthur and Guggenheim fellowships; the Kennedy Center Honors; and Grammy, Emmy, Academy, and Tony awards.

Dr. Blaser is a world renowned researcher in microbiology and infectious disease. His work over the past three decades has helped transform our understanding of the human microbiome, the bacteria that live on and inside us. In particular, his lab has helped untangle the complex molecular behavior of Helicobacter pylori, a widespread species of bacteria linked to gastritis, peptic ulcers and stomach cancer. In addition to developing the first blood test for H. pylori, his team has recast the microbe in a new light, showing how its depletion in the gut through the use of antibiotics increases the risk of childhood asthma. Dr. Blaser holds 24 U.S. patents relating to his research into bacterial diseases and the microbiome, and has authored over 500 original articles.

Martin Blaser has made invaluable contributions not only to the study of the microbiome and disease, but as an educator and mentor to many fellow scientists, said Dafna Bar-Sagi, PhD, senior vice president and vice dean for Science and chief scientific officer at NYU School of Medicine. Through his leadership and intangible interpersonal qualities as well as his research, he stands out as a model for the scientific community and beyond. His election to the AMACAD is richly deserved."

Dr. Blaser is the principal investigator on five peer reviewed grants, including three from the NIH, and serves as chair of the Advisory Board for Clinical Research at the NIH. Dr. Blaser also leads the Human Microbiome Program at NYU Langone.

Dr. Blaser is a member of the American Society for Clinical Investigation, the Association of American Physicians, the American Epidemiologic Society, and the American Clinical and Climatological Association, as well as a Governor of the American Academy of Microbiology and a Master of the American College of Physicians. He currently serves as the Chair of the Advisory Board for Clinical Research of the National Institutes of Health, and the Scientific Advisory Board of the Doris Duke Charitable Foundation. Previously he served as president of the Infectious Diseases Society of America and as Chair of the Board of Scientific Counselors of the National Cancer Institute.

###

About NYU School of Medicine: NYU School of Medicine is one of the nations preeminent academic institutions dedicated to achieving world class medical educational excellence. For 170 years, NYU School of Medicine has trained thousands of physicians and scientists who have helped to shape the course of medical history and enrich the lives of countless people. An integral part of NYU Langone Medical Center, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research and direct patient care. The School also maintains academic affiliations with area hospitals, including Bellevue Hospital Center, one of the nations finest municipal hospitals where its students, residents and faculty provide the clinical and emergency care to New York Citys diverse population, which enhances the scope and quality of their medical education and training. Additional information about the NYU School of Medicine is available at http://school.med.nyu.edu/.

Read this article:
American Academy of Arts and Sciences Elects Martin J. Blaser, MD, Professor of Medicine and Microbiology, to 2013 ...

Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market – Video

Posted on by


Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market
For More Information Kindly Visit On : http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/2013-analysis-of-the-spanish-micro...

By: Deepa Kamath

Read the original:
Bharat Book Presents : 2013 Analysis of the Spanish Microbiology Testing Market - Video

Largest EU Prevalence Study of Clostridium Difficile Infection Reveals That More Than One Fifth of Patients May …

Posted on by

infections in hospitals[2],[3]

First results from EUCLID, the largest ever prevalence study of CDI across Europe, were presented today at the 23rd European Congress of Clinical Microbiology and Infectious Disease (ECCMID). Data reveal that an incorrect diagnosis may be made for more than one in five hospitalised patients with diarrhoea, who could have CDI.[4] This potentially may lead to inappropriate or inadequate treatment.[4] CDI can be severe and hospital patients with CDI are up to three times more likely to die in hospital (or within a month of infection) than those without CDI.[5],[6]

The EUropean multi-centre, prospective bi-annual point prevalence study of CLostridium difficile Infection in hospitalised patients with Diarrhoea (EUCLID) involved 482 hospitals from 20 European countries. In total 3,920 faecal samples were submitted by participating hospitals to the EUCLID National Coordinating laboratory (NCLs). Nearly one in four (24.6%) samples found to be positive for C. difficile at the NCL had not been tested at the local hospital level and 47 (2.3%) patients found to be positive for C. difficile at the NCL were tested at the hospital but received an incorrect negative result. Notably, only 10.6% of hospitals tested all diarrhoeal faecal in-patient samples, and only 27.4% used an optimised CDI algorithm for routine testing.[4]

"In this study we saw that on one day alone, 82 patients with CDI were not diagnosed due to a lack of laboratory testing or clinical suspicion, and in total 246 patients received an incorrect result", said Professor Mark Wilcox, Professor of Medical Microbiology, Leeds Teaching Hospitals & University of Leeds. "These results show that there is still more to be done to improve the way CDI is currently being tested in hospitals across Europe."

The EUCLID study is being coordinated out of the University of Leeds, UK, by Professor Mark Wilcox's research group, with support from the EUCLID Core Group. The study is funded by Astellas Pharma Europe Ltd. Participating hospitals submitted samples of all un-formed faeces received on a single day to the NCL regardless of whether they had been tested within the hospital. Each NCL then tested all samples using a 2-stage CDI algorithm, with the results from the hospital and NCL then compared for each sample.[4]

In this study, the average incidence rate of CDI across Europe was 6.6 per 10,000 patient bed days.[4] This is substantially higher than a previous pan-European surveillance study, the European Clostridium Infection Survey (ECDIS) performed in 2008-2009 which found an average incidence rate of 4.1 per 10,000 patient bed days.[7] There were also wide discrepancies between the numbers of samples tested for C. difficile within hospitals; the highest rate of 97% of samples tested was found in the Czech Republic with the lowest of 0% in Bulgaria.[4] Surprisingly hospitals in the UK only tested 75% of samples despite national guidance to test all unformed stools from inpatients.[4]

"CDI is an important patient safety issue and also creates a significant economic burden for hospitals and health systems", comments Professor Mark Wilcox. "It is important that optimal methods of diagnosis are in place, as errors may lead to inappropriate or inadequate treatment of patients and inadequate infection control measures."

A second sampling and testing wave will take place during the Summer of 2013 with the full results and analysis expected to be available in 2014.

About Clostridium difficile Infection

CDI is a serious illness resulting from infection of the internal lining of the colon by C. difficile bacteria. The bacteria produce toxins that cause inflammation of the colon, diarrhoea and, in some cases, death.[8] Patients typically develop CDI after the use of broad-spectrum antibiotics that disrupt normal bowel flora, allowing C. difficile bacteria to flourish.[8],[9] CDI is the leading cause of hospital acquired (nosocomial) diarrhoea in industrialised countries[10] and the risk of CDI and disease recurrence is particularly high in patients aged 65 years and older.[11]Recurrence of CDI occurs in up to 25% of patients within 30 days of initial treatment with current therapies.[12],[13],[ 14] The ESCMID has identified recurrence as being the most important problem in the treatment of CDI.[15]

Original post:
Largest EU Prevalence Study of Clostridium Difficile Infection Reveals That More Than One Fifth of Patients May ...

BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement

Posted on by

SPARKS, Md., April 27, 2013 /CNW/ - BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today an international distributor agreement with Bruker Daltonics Inc. to sell and provide front-line technical support for the co-labeled BD Bruker MALDI Biotyper System.

Microbial identification and antimicrobial susceptibility testing is the end-point of the majority of work a microbiology lab performs on a daily basis and is very time consuming. The BD Bruker MALDI Biotyper System combined with automated antimicrobial susceptibility testing on the BD Phoenix Microbiology System and the BD EpiCenter Microbiology Data Management System, will facilitate a fully integrated, optimized approach for laboratory workflow.

"BD believes mass spectrometry technologies are the future of microbial identification," said Jamie Condie , Vice President and General Manager, BD Diagnostics Diagnostic Systems, Infectious Disease. "Combining Bruker's expertise in this area with our advanced lab automation experience, the BD Bruker MALDI Biotyper System will enhance our customers' clinical decision making and laboratory workflow."

Antimicrobial susceptibility testing is conducted via traditional automated systems such as the BD Phoenix System. The combination of these two proven technologies, the BD Phoenix System and the Bruker MALDI Biotyper, and data management through the BD EpiCenter System, will provide laboratorians with a new approach to identification and susceptibility testing, which is expected to reduce the turnaround time for critical diagnostic results, while also improving laboratory efficiency and costs. Identification of pathogens will occur in minutes versus hours directly impacting patient management.

The Bruker MALDI Biotyper is currently not available in the United States for in vitro diagnostic use.

This announcement is an update to the joint collaboration, co-marketing, and co-selling agreement with Bruker Daltonics Inc. in 2010.

About the BD Bruker MALDI Biotyper SystemThe dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States of America the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes , New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

Contact: Jamie Yacco Public Relations +1 (201) 847-4796 Email: Jamie_Yacco@bd.com

SOURCE: BD-Becton Dickinson

Read this article:
BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement


  1. Microbiology